C4X Discovery Holdings plc
(“C4XD”, “C4X Discovery” or the “Company”)
Result of General Meeting and Issue of Equity
Total Voting Rights
9 November 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce that at the General Meeting held earlier today in connection with the Company’s Placing at an Issue Price of 14.0 pence, details of which were announced on 21 October 2020, each of the Resolutions were duly passed.
As a consequence and conditional on, amongst other things, Admission, the Company has raised approximately £15.0 million (before expenses and excluding any proceeds arising from the exercise of the Warrants) in aggregate through the issue of 99,169,286 Units and 7,973,572 EIS/VCT Placing Shares.
Application has been made for the 107,142,858 Placing Shares to be admitted to trading on AIM. It is expected that First Admission, in respect of 7,973,572 EIS/VCT Placing Shares, will take place at 8.00 a.m. on 10 November 2020 and that Second Admission, in respect of 99,169,286 General Placing Shares, will take place at 8.00 a.m. on 11 November 2020. The 99,169,286 Warrants will be unlisted and no application will be made for the Warrants to be admitted to trading on AIM.
Total voting rights
Following Second Admission, the total issued ordinary share capital of the Company will consist of 226,346,002 Ordinary Shares. The Placing Shares will rank pari passu with the existing ordinary shares of the Company. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company will be 226,346,002. The above figure of 226,346,002 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at approximately 7.06 a.m. on 21 October 2020 unless otherwise stated.
The person responsible for arranging the release of this information is Clive Dix, CEO of the Company.